Valuation: Elicio Therapeutics, Inc.

Market Cap 71.52M 62.82M 57.88M 54.12M 102M 6.75B 103M 694M 269M 3.33B 269M 263M 11.56B P/E 2026 *
-1.75x
P/E 2027 * -1.42x
Enterprise Value 71.52M 62.82M 57.88M 54.12M 102M 6.75B 103M 694M 269M 3.33B 269M 263M 11.56B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
70.18%
Yield 2026 *
-
Yield 2027 * -
1 day-5.78%
1 week-2.60%
Current month-67.22%
1 month-62.31%
3 months-65.78%
6 months-54.21%
Current year-52.89%
1 week 3.58
Extreme 3.58
4.49
1 month 2.66
Extreme 2.66
16
Current year 2.66
Extreme 2.66
16
1 year 2.66
Extreme 2.66
16
3 years 2.66
Extreme 2.66
16
5 years 2.66
Extreme 2.66
24.39
10 years 2.66
Extreme 2.66
24.39
Manager TitleAgeSince
Chief Executive Officer 66 2018-09-30
Director of Finance/CFO 54 2025-03-23
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 66 2018-09-30
Director/Board Member 54 2023-05-31
Chairman 71 2016-12-31
Date Insider Type Main position Quantity % Market Cap.
02-01Free

Chief Executive Officer

220,800 1.2625%
02-01Free

Chief Financial Officer

71,900 0.4111%
02-01Free

Chief Technology Officer

62,400 0.3568%
Change 5-day change 1-year change 3-year change Capi.($)
-5.78%-2.60%-53.24%-62.98% 75.91M
+1.67%+8.90%-5.75%+1.40% 45.45B
+4.95%+9.31%+363.86%+598.16% 36.09B
-0.64%+1.92%+3.08%+53.58% 30.81B
+0.44%+11.12%+17.47%-12.91% 30.98B
+0.23%-0.86%+12.75%+21.10% 24.62B
+9.90%+13.32% - - 14.78B
+1.40%+12.99%+67.11%+132.76% 14.65B
+1.88%+8.59%+13.76%+20.68% 13.3B
+2.38%+5.69%+95.85%+97.63% 12.65B
Average +1.64%+5.65%+57.21%+94.38% 22.34B
Weighted average by Cap. +2.13%+6.68%+77.63%+128.81%

Financials

2026 *2027 *
Net sales - -
Net income -43.68M -38.36M -35.35M -33.05M -61.99M -4.12B -63.12M -424M -164M -2.03B -164M -160M -7.06B -57.53M -50.54M -46.56M -43.54M -81.65M -5.43B -83.15M -559M -216M -2.68B -216M -211M -9.3B
Net Debt - -
Logo Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Employees
33
Date Price Change Volume
26-06-25 US$3.750 -5.78% 907,818
26-06-24 US$3.980 -3.16% 760,981
26-06-23 US$4.110 -0.72% 1,565,118
26-06-22 US$4.140 +7.53% 3,182,945
26-06-18 US$3.850 -18.26% 5,435,699
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.750USD
Average target price
20.67USD
Spread / Average Target
+451.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELTX Stock